• AAPL 169.3
  • TSLA 168.29
  • AMZN 179.62
  • MSFT 406.32
  • INTC 31.88
  • EURUSD 1.0699
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. BR /
  3. HYL.BR

Hyloris Developmentsen Sa (HYL BR) stock market data APIs

€11.9 0.2(1.7%) as of April 26, 2024

Hyloris Developmentsen Sa Financial Data Overview

11.7
11.9
-
11.9
11.7
10.6-14.1
330 M
28 000 K
2 814 K
-0.38
0.576
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'HYL',
Type: 'Common Stock',
Name: 'Hyloris Developmentsen Sa',
Exchange: 'BR',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Belgium',
CountryISO: 'BE',
OpenFigi: NULL,
ISIN: 'BE0974363955',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Hyloris Developmentsen Sa Fundamental Data is available in our Financial Data APIs

  • Net Revenue 2 814 K
  • EBITDA -15 740 000
  • Earnings Per Share -0.56
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Hyloris Developmentsen Sa Earnings via APIs

  • Latest Release 2023-03-15
  • EPS/Forecast 0

Get Hyloris Developmentsen Sa End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Hyloris Developmentsen Sa latest news via APIs

Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada

Territorial expansion for a product candidate previously exclusively targeting the U.S.Kye Pharmaceuticals to register and commercialize in Canada Liège, Belgium – 24 October 2023 – 7AM CET – ...
  • 505B2
  • ATOMOXETINE
  • BRUSSELS STOCK EXCHANGE:HYL
  • CANADA
  • COMPANY ANNOUNCEMENT
  • EUROPEAN REGULATORY NEWS
  • HYLORIS
  • HYLORIS PHARMACEUTICALS SA
  • PHARMACEUTICALS

Hyloris announces U.S. FDA Approval of Maxigesic® IV

Maxigesic® IV, a potent non-opioid painkiller, to be marketed in the U.S. under the tradename Combogesic® IVFirst U.S. sales expected in early 2024, triggering a milestone payment of USD 2,1 million...
  • BRUSSELS STOCK EXCHANGE:HYL
  • CLINICAL STUDY
  • COMPANY ANNOUNCEMENT
  • COMPANY REGULATORY FILINGS
  • EUROPEAN REGULATORY NEWS
  • FDA
  • FDA APPROVAL
  • HEALTH
  • HYLORIS
  • HYLORIS PHARMACEUTICALS SA
  • MAXIGESIC IV
  • STOCK MARKET NEWS
Do you have any questions?
support@eodhistoricaldata.com